Kymera Therapeutics (NASDAQ:KYMR) Issues Earnings Results, Misses Estimates By $0.06 EPS

Kymera Therapeutics (NASDAQ:KYMR) announced its earnings results on Thursday. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.06), FiscalAI reports. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%. The company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $3.28 million. During the same period in the prior year, the business earned ($0.94) earnings per share. The firm’s revenue for the quarter was up .0% on a year-over-year basis.

Here are the key takeaways from Kymera Therapeutics’ conference call:

• KT-579 showed robust human proof of mechanism: once-daily dosing produced more than 90% IRF5 degradation in the top dose cohorts, including comparable effects in skin, with substantial reductions across inflammatory cytokine, interferon, and B-cell pathways.
• KT-579 was well tolerated in the phase I study, with a safety profile comparable to placebo, no serious adverse events, no discontinuations, and no infection imbalance. Kymera plans to advance the program into the approximately 30-patient LUMORA phase Ib lupus trial by early 2027.
• The company completed the 16-week placebo-controlled portion of the KT-621 BROADEN2 atopic dermatitis study and expects to report results by year-end; 98% of eligible patients entered the 52-week open-label extension. Kymera is preparing for a potential phase III AD study beginning by mid-2027, subject to supportive results and FDA alignment.
• KT-621 asthma enrollment is progressing as planned, with phase IIb BREADTH results expected in late 2027, while partner programs KT-485 and KT-200 also remain on track. Management emphasized potential expansion into additional type 2 inflammatory diseases, but detailed plans will depend on upcoming clinical data.
• Kymera ended September with approximately $1.6 billion in cash and investments, providing a projected runway into 2029 and funding planned KT-621 phase III preparations, the KT-579 lupus study, and continued pipeline research without near-term financing pressure.

Kymera Therapeutics Stock Performance

NASDAQ KYMR traded up $0.53 on Friday, hitting $123.13. The stock had a trading volume of 564,175 shares, compared to its average volume of 747,942. The company has a market capitalization of $10.24 billion, a price-to-earnings ratio of -38.18 and a beta of 1.98. Kymera Therapeutics has a 52-week low of $55.66 and a 52-week high of $130.05. The firm has a 50-day moving average of $114.83 and a 200-day moving average of $96.08.

Insider Buying and Selling

In related news, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the completion of the sale, the chief executive officer directly owned 666,568 shares in the company, valued at $75,855,438.40. This represents a 4.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Brian Adams sold 6,371 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $116.83, for a total value of $744,323.93. Following the completion of the sale, the insider owned 50,254 shares in the company, valued at approximately $5,871,174.82. This represents a 11.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 15.98% of the company’s stock.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Encouraging KT-579 Phase 1 results: Kymera reported that KT-579 produced deep, sustained IRF5 degradation, strong changes in disease-relevant biomarkers and a favorable safety profile in healthy volunteers. The findings provide early validation for the company’s immunology pipeline and degrader technology. Kymera Q3 results and KT-579 Phase 1 results
• Positive Sentiment: Truist raised its price target: Truist Financial reaffirmed a “buy” rating and increased its target to $150 from $136, implying meaningful potential upside based on the latest clinical and corporate developments. Truist raises Kymera price target
• Positive Sentiment: Additional bullish analyst action: BTIG Research raised its target to $139 from $134 and maintained a “buy” rating, adding to the positive analyst commentary surrounding KYMR. BTIG analyst action
• Neutral Sentiment: Mixed analyst view: Royal Bank of Canada lifted its target to $116 from $112 but kept a “sector perform” rating. The revised target remains below the recent trading level, signaling more cautious expectations than Truist and BTIG. RBC analyst action
• Neutral Sentiment: Pipeline update: Kymera also provided an update on the ongoing KT-621 Phase 1 formulation study. Investors are likely focused on future dosing, safety and efficacy data as the program advances. KT-621 formulation study update
• Negative Sentiment: Quarterly results missed expectations: Kymera reported a third-quarter loss of $1.32 per share versus the $1.26 consensus estimate, while revenue of $1.35 million fell short of the $3.28 million forecast. The loss also widened from $0.94 per share a year earlier, underscoring the company’s ongoing cash-burn and development-stage risks. Kymera Q3 net loss

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Truist Financial reissued a “buy” rating and issued a $150.00 price objective (up from $136.00) on shares of Kymera Therapeutics in a research note on Friday. Stifel Nicolaus boosted their target price on Kymera Therapeutics from $132.00 to $152.00 and gave the company a “buy” rating in a research report on Tuesday, September 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Thursday, October 15th. Morgan Stanley upped their price objective on shares of Kymera Therapeutics from $135.00 to $146.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Royal Bank Of Canada increased their price objective on Kymera Therapeutics from $112.00 to $116.00 and gave the stock a “sector perform” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $137.92.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.